Layn(002166)2024-10-30 08:53Revenue and Profitability - Revenue for Q3 2024 reached ¥444,476,543.36, an increase of 17.96% year-over-year, and total revenue for the year-to-date is ¥1,169,965,060.76, up 31.61% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥36,728,643.32, a significant increase of 680.75% year-over-year, with a year-to-date net profit of ¥101,621,708.59, up 148.46%[2] - The net profit excluding non-recurring items for Q3 2024 was ¥39,165,818.22, reflecting an increase of 11,411.63% year-over-year, and the year-to-date figure is ¥104,525,118.79, up 2,789.46%[2] - Basic earnings per share for Q3 2024 were ¥0.05, a 400.00% increase year-over-year, with year-to-date earnings per share at ¥0.14, up 133.33%[2] - The company's operating revenue for the first nine months of 2024 reached ¥1,169,965,060.76, a 31.61% increase compared to ¥888,977,405.17 in the same period of 2023[7] - The plant extraction business generated operating income of CNY 1,148.47 million, reflecting a year-on-year growth of 29.21%[11] - Net profit attributable to shareholders reached CNY 101.62 million, marking a significant year-on-year increase of 148.46%[11] - The company reported a total comprehensive income of CNY 103,935,605.85, compared to CNY 73,421,891.74 in the previous year, reflecting a growth of 41.7%[20] - Earnings per share (EPS) for the period was CNY 0.14, up from CNY 0.06 in the previous year, reflecting improved profitability[20] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥4,940,440,819.53, representing a 6.81% increase from the end of the previous year[2] - Shareholders' equity attributable to the parent company was ¥3,039,897,697.20, a decrease of 2.93% compared to the end of the previous year[2] - The total liabilities rose to CNY 1,823,351,558.04, compared to CNY 1,421,120,433.26 in the previous year, marking an increase of 28.3%[20] - The total equity attributable to shareholders of the parent company decreased to CNY 3,039,897,697.20 from CNY 3,131,659,215.31, a decline of 2.9%[20] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥142,736,454.08, an increase of 29.92% compared to the same period last year[2] - The company reported a significant increase in cash and cash equivalents, with a 139.17% rise in cash holdings due to increased sales collections[5] - The net cash flow from investing activities improved by 59.55%, with a net outflow of ¥147,738,563.43 compared to ¥365,269,140.15 in the previous year, primarily due to reduced external investments[8] - The net cash flow from financing activities surged by 411.24% to ¥89,353,855.25, driven by an increase in net bank loans[8] - The net increase in cash and cash equivalents was ¥85,649,220.62, a 130.32% improvement from a net decrease of ¥282,447,261.92 in the same period last year[8] - The cash inflow from operating activities reached CNY 1,521,695,626.79, an increase of 47.3% compared to CNY 1,032,920,684.97 in the previous period[22] - The cash outflow for investing activities totaled CNY 157,657,032.66, significantly reduced from CNY 384,966,235.51 in the prior period, indicating a decrease of 59.0%[22] - The cash inflow from financing activities amounted to CNY 852,656,045.00, compared to CNY 662,732,899.50, representing a growth of 28.7%[23] Research and Development - Research and development expenses increased by 35.73% to ¥47,363,853.57 from ¥34,894,502.03 year-on-year, indicating a significant investment in innovation[7] - The synthetic biology workshop commenced operations on September 20, 2024, with a total investment of approximately CNY 210 million, expected to produce over 1,000 tons of synthetic biological products annually, generating over CNY 1 billion in annual output value[14] - The company established a collaboration with Jiangnan University to create a synthetic biology technology transformation base, enhancing its research and industrialization capabilities[15] - The company aims to enhance its competitive advantage in the natural health ingredient biosynthesis field through the dual technology route of natural extraction and biosynthesis[15] Tax and Fees - The company reported a significant decrease in tax and additional fees by 51.50%, from ¥6,539,380.75 to ¥3,171,474.18, mainly due to the absence of property tax payments by overseas subsidiaries[7] - The company’s income tax expense increased by 107.37% to ¥21,727,600.37, reflecting a rise in total profit[7] - The company received CNY 66,130,272.44 in tax refunds, a decrease of 12.2% from CNY 75,374,232.68 in the previous period[22]